

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re application of: **Drewery, et al.**International App. No.: **PCT/US2004/023680** Group Art Unit:International Filing Date: **July 23, 2004** Examiner:For: **CHEMICAL COMPOUNDS****Commissioner for Patents
Washington, D.C. 20231****INFORMATION DISCLOSURE STATEMENT**

Applicants request that the references identified on Form PTO-1449 appended hereto be considered by the Examiner and officially made of record in accordance with the provisions of 37 CFR 1.97

Copies of the references are enclosed
 Copies of the references were submitted in parent application Serial No. _____. (37 CFR 1.98(d))
 A copy of the International Search Report which issued on International Application No. PCT/US2004/023680 is submitted herewith. All of the publications cited in the International Search Report are listed on the attached form PTO-1449 and Applicants understand that copies have been supplied to the U.S. Patent Office by the International Bureau.

A. The Information Disclosure Statement submitted herewith is being filed within three months of the filing date of the above application or date of entry into the national stage of an international application or before the mailing date of a first Office action on the merits, whichever event occurs last. 37 CFR 1.97(b).

OR

The Information Disclosure Statement submitted herewith is being filed before the mailing of a first office action after the filing of a Request For Continued Examination under 37 C.F.R. 1.114 (37 C.F.R. 1.97(b)(4)).

B. The Information Disclosure Statement transmitted herewith is being filed after three months of the filing date of the above application or the date of entry into the national stage as set forth in § 1.491 of an international application or after the mailing date of the first Office Action on the merits, whichever event occurred last, but before the mailing date of either:

(1) a final action under § 1.113 or

(2) a notice of allowance under § 1.311,
whichever occurs first.

Applicant hereby certifies that each item of information contained in this Information Disclosure Statement was cited in a communication from a foreign patent office in a counterpart foreign application not more than three months prior to the filing of this statement.

Applicant elects the option to pay the fee set forth in 37 CFR 1.17(p) for submission of an Information Disclosure Statement under § 1.97(c) (\$240.00).

C. The Information Disclosure Statement transmitted herewith is being filed after a final action under § 1.113, or a notice of allowance under § 1.311, whichever occurs first, but before the payment of the issue fee. Also enclosed is a copy of the International Search Report which Issued on International Publication No.

In accordance with the requirements of 37 CFR 1.97(d):

Applicant hereby certifies that each item of information contained in this Information Disclosure Statement was cited in a communication from a foreign patent office in a counterpart foreign application not more than three months prior to the filing of this statement.

Applicant hereby petitions for the consideration of the accompanying Information Disclosure Statement. 37 CFR 1.97(d)(ii).

The petition fee set forth in § 1.17(i)(1) (\$130.00) is submitted herewith.

Please charge any required fees to Deposit Account No.07-1392.

A duplicate copy of this paper is attached.

Respectfully Submitted,

Kathryn L. Coulter

Kathryn L. Coulter
Attorney for Applicant
Registration No. 45,889

Date: 1/25/2006

GlaxoSmithKline
Corporate Intellectual Property
5 Moore Drive, P.O. Box 13398
Research Triangle Park, NC 27709-3398
Telephone: (919) 483-1467
Facsimile: (919) 483-7988

FORM PTO-1449 INFORMATION DISCLOSURE STATEMENT				ATTORNEY DOCKET NO.		INTERNATIONAL APP. NO. 5004		
				PR60418USW		PCT/US2004/023680		
				APPLICANT				
				Drewery et al.				
INTERNATIONAL FILING DATE 7/23/04				GROUP				
U.S. PATENT DOCUMENTS								
Examiner Initials		Patent Number	Issue Date	Name		Class	Subclass	Filing Date If Appropriate
	1	6,001,865	12/14/99	Silvestrini et al.				
Continue on page _____								
FOREIGN PATENT DOCUMENTS								
		Document Number	Publication Date	Country		Class	Subclass	Translation Yes No
	2	99/06375	2/11/99	PCT				
Continue on page _____								
OTHER DOCUMENTS (Including Author, Title, Journal-Date, Page Number, Etc.)								
	3	Collot et al., "Heck cross-coupling reaction of 3-iodoindazoles with methyl acrylate: a mild and flexible strategy to design 2-azatryptamines," <i>Teatrhedron Letters</i> , 2000, Vol. 41, pp. 4363-4366.						
Continue on page _____								
EXAMINER				DATE CONSIDERED				
EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP § 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to the applicant.								